In vitro activity of the semisynthetic glycopeptide amide MDL 63,246.
AUTOR(ES)
Kenny, M T
RESUMO
The in vitro activity of the semisynthetic glycopeptide amide MDL 63,246 against 293 U.S. clinical isolates of gram-positive cocci was determined by the broth microdilution method. When compared with teicoplanin, MDL 63,246 had improved activity against Staphylococcus epidermidis (MICs that inhibited 90% strains tested [MIC90s], 0.25 versus 8 micrograms/ml, respectively). Staphylococcus haemolyticus (MIC90s, 1 versus 32 micrograms/ml, respectively), and VanA Enterococcus faecium (MIC90s, 32 versus > or = 1,024 micrograms/ml, respectively).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=162786Documentos Relacionados
- Antimicrobial activity of MDL 63,246, a new semisynthetic glycopeptide antibiotic.
- Pharmacokinetics of MDL 63,246, a new semisynthetic glycopeptide antibiotic, in the rat.
- In vitro activities of three semisynthetic amide derivatives of teicoplanin, MDL 62208, MDL 62211, and MDL 62873.
- In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
- Antimicrobial activity of MDL 62,873, a semisynthetic derivative of teicoplanin, in vitro and in experimental infections.
